Last reviewed · How we verify

Austrian Breast & Colorectal Cancer Study Group — Portfolio Competitive Intelligence Brief

Austrian Breast & Colorectal Cancer Study Group pipeline: 0 marketed, 0 filed, 3 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 3 Phase 3 2 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Fluorouracil implant Fluorouracil implant phase 3 Antimetabolite chemotherapy agent Thymidylate synthase Oncology
Tamoxifen alone Tamoxifen alone phase 3 Selective estrogen receptor modulator (SERM) Estrogen receptor alpha (ERα) Oncology
Tamoxifen + Aminoglutethimide Tamoxifen + Aminoglutethimide phase 3 SERM and CYP11A1 inhibitor estrogen receptor Oncology

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. AstraZeneca · 1 shared drug class
  2. Estetra · 1 shared drug class
  3. Fundació Privada Eugin · 1 shared drug class
  4. H. Lee Moffitt Cancer Center and Research Institute · 1 shared drug class
  5. National Taiwan University Hospital · 1 shared drug class
  6. Oregon Health and Science University · 1 shared drug class
  7. Samsung Medical Center · 1 shared drug class
  8. Shandong Suncadia Medicine Co., Ltd. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Austrian Breast & Colorectal Cancer Study Group:

Cite this brief

Drug Landscape (2026). Austrian Breast & Colorectal Cancer Study Group — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/austrian-breast-colorectal-cancer-study-group. Accessed 2026-05-17.

Related